Bay State startup Neograft closed an $11 million equity funding round in support of its vascular sleeve technology.
Neograft’s Angioshield device "creates a micro-fibrous, polymer sleeve intimately surrounding the outside surface of a harvested vein to mechanically reinforce and protect it from overdilation," according to the company. The technology is not yet approved for clinical use.